- Advertise
- Contact Us
- Editorial Info
- Terms and Conditions
- Privacy Policy
- Do Not Sell My Personal Information
© 2022 MJH Life Sciences™ and Practical Cardiology. All rights reserved.
Heart Failure
The Practical Cardiology(TM) Heart Failure clinical resource center is an information hub for the latest in heart failure and heart failure management. With a focus on heart failure with reduced and preserved ejection fraction (HFrEF and HFpEF) this page features content including articles, videos, podcasts, and clinician-authored columns on FDA approvals, studies, guideline updates, and more.
Cardiology Month in Review: October 2022
October 29, 2022
The October 2022 cardiology month in review features the top content from HFSA 2022, new data related to antithrombotic therapy in atrial fibrillation, and shining a spotlight on the AHA’s scientific statement on patient-reported outcomes in peripheral artery disease.
County-Level Food Insecurity Linked to Increased Heart Failure Mortality Rates
October 26, 2022
An analysis of data from more than 2900 counties in the US is providing clinicians with new insight into the impact of social determinants of health, namely food insecurity, might influence heart failure mortality rates on a population level across the US.
Black Patients with Heart Failure Half as Likely to Receive Device Therapy, Transplant as White Patients
October 19, 2022
Despite no differences in patient preferences, an analysis from the National Institutes of Health suggests Black patients with heart failure were 55% less likely than their White counterparts to receive a ventricular assist device or transplantation.
Furosemide Injection Could Improve Congestion Management in Heart Failure Without Need for Hospitalization
October 07, 2022
Data from the AT-HOME HF pilot study presented at HFSA 2022 provide insight into the effects of furosemide injection 8 mg/mL on congestion management among patients with heart failure ahead of the agent's October 8 PDUFA date.
Trends in Device Therapy for Heart Failure, with Andrew Sauer, MD
October 06, 2022
At HFSA 2022, Andrew Sauer, MD, provides perspective on contemporary trends in device therapy in heart failure, including recommendations made within the 2022 ACC/AHA/HFSA heart failure guidelines.
8-in-10 Medicare Beneficiares Hospitalized with HFpEF Could be Considered Candidates for Dapagliflozin
October 04, 2022
An analysis applying data from the DELIVER trial to the Get With The Guidelines-Heart Failure Registry suggests 81% of hospitalized Medicare beneficiaries with HFpEF could be considered candidates for dapagliflozin use under a potential FDA label expansion.
Dapagliflozin's Benefit in HFpEF Reaches Significance Within 2 Weeks, Study Finds
October 03, 2022
A prespecified analysis of the DELIVER trial presented at HFSA 2022 indicates dapagliflozin provides early benefit in patients with heart failure with preserved ejection fraction, with the effect on the trial's primary end point evident in just 13 days.
Sacubitril/Valsartan Use Could Reduce Mitral Regurgitation in HFrEF
October 03, 2022
An analysis of data from the PROVE-HF trial suggests use of sacubitril/valsartan was associated with a reduction in prevalence of mitral regurgitation among patients with heart failure with reduced ejection fraction.
Optimizing Initiation of GDMT for Heart Failure, with Stephen Greene, MD
October 02, 2022
After a presentation on cost considerations and outcomes at HFSA 2022, Stephen Greene, MD, provides perspective on the current state of optimization for GDMT in heart failure.
Sotagliflozin Reduces Risk of Recurrent Heart Failure Events
October 02, 2022
New sotagliflozin data at HFSA 2022 provides insight into the apparent reduction in recurrent heart failure events achieved in the SOLOIST-WHF trial. Deepak Bhatt, MD, MPH, provides perspective on the potential role of the dual SGLT1/2 inhibitor, based on trial data, if approved by the US Food and Drug Administration.